oral weight loss pill

Business news, market intelligence, and global industry analysis.

The Latest

Representative image of military and commercial vessels near the Strait of Hormuz, illustrating Iran’s renewed control measures after reversing its brief claim that the waterway was fully open to commercial shipping.

Iran reverses Hormuz opening within 24 hours — IRGC fires on tankers as blockade standoff deepens

Representative image of a legal and workplace rights dispute in India after the National Human Rights Commission notices and the Supreme Court filing intensified focus on the Nashik workplace harassment and coercion case involving Tata Consultancy Services.

TCS Nashik case: NHRC directs three-year POSH audit across all TCS branches

Nexstar Media Group (NASDAQ: NXST) faces post-closing merger shock as judge halts TEGNA integration

Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling

Neumora (NASDAQ: NMRA) to begin Phase 1 trial of oral NLRP3 obesity pill in early 2026: Can it rival GLP-1 pills?

Find out how Neumora Therapeutics’ oral obesity candidate NMRA‑215 is advancing to human trials. Could it reshape the future of weight loss therapies?

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

October 28, 2025